Acute Myeloid Leukemia (AML) (outsource Genetech) at Chughtai Lab

Acute Myeloid Leukemia (AML) (outsource Genetech) at Chughtai Lab

Acute Myeloid Leukemia (AML) is a rapid, aggressive hematological malignancy characterized by the clonal expansion of immature myeloid precursors (blasts) in the bone marrow and peripheral blood. This proliferation impairs normal hematopoiesis, leading to severe cytopenias, including anemia, neutropenia, and thrombocytopenia. To manage this complex disease, precise molecular and genetic characterization is essential. The Acute Myeloid Leukemia (AML) (outsource Genetech) test at Chughtai Lab is a highly specialized diagnostic panel designed to identify key genetic mutations, chromosomal translocations, and molecular markers that define the unique biological profile of a patient’s leukemia. By outsourcing this advanced testing to Genetech, a premier reference laboratory specializing in high-complexity molecular diagnostics, Chughtai Lab provides patients and oncologists in Pakistan with access to cutting-edge technologies like Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), and Fluorescence In Situ Hybridization (FISH). This comprehensive panel evaluates critical genes such as FLT3, NPM1, CEBPA, IDH1, IDH2, and TP53, alongside cytogenetic abnormalities. The diagnostic value of this panel is immense, as it not only confirms the diagnosis of AML but also provides critical prognostic risk stratification, guides the selection of targeted therapies, and establishes a baseline for monitoring minimal residual disease (MRD). Understanding the molecular landscape of AML allows hematologists to transition from a one-size-fits-all treatment approach to personalized precision medicine, significantly improving patient outcomes and survival rates.

Clinical Procedure: What to Expect

Patient Preparation

• Provide Clinical History: Patients must provide a comprehensive clinical history, including recent complete blood count (CBC) results, peripheral blood smear findings, and any previous bone marrow aspirate reports.
• Informed Consent: A signed informed consent form is mandatory, as this test involves genetic and molecular analysis.
• Dietary Instructions: While fasting is generally not required for either peripheral blood collection or bone marrow aspiration, patients should follow any specific dietary instructions provided by their referring physician.
• Medication Review: Patients must inform their healthcare provider of all current medications, particularly anticoagulants or antiplatelet drugs such as aspirin, clopidogrel, warfarin, or low-molecular-weight heparin, as these may need to be temporarily discontinued prior to a bone marrow biopsy to minimize bleeding risks.
• Comfortable Clothing: Patients should wear comfortable, loose-fitting clothing on the day of the procedure, especially if a bone marrow biopsy is scheduled.
• Previous Records: It is highly recommended to bring all previous medical records, hematology consultation notes, and prior diagnostic reports to the Chughtai Lab collection center to facilitate accurate clinical correlation.

During the Procedure

The sample collection process depends on whether peripheral blood or bone marrow is utilized. For peripheral blood collection, a highly trained phlebotomist at Chughtai Lab performs a standard venipuncture. The skin over a prominent vein, usually in the antecubital fossa of the arm, is cleansed with an antiseptic solution. A sterile needle is inserted, and blood is drawn into specialized collection tubes containing anticoagulants like EDTA or sodium heparin. The procedure is quick, lasting only a few minutes, and involves minimal discomfort. For bone marrow collection, the procedure is performed by a qualified hematologist or oncologist in a sterile clinical environment. The patient is positioned comfortably, typically lying on their side (lateral decubitus) or stomach (prone). The clinician identifies the posterior superior iliac spine (pelvic bone), cleanses the area, and administers a local anesthetic to numb the skin, subcutaneous tissue, and the periosteum of the bone. Once the area is fully anesthetized, a specialized bone marrow aspiration needle is inserted through the bone cortex into the marrow cavity. A syringe is attached, and a small volume of liquid bone marrow is aspirated. The patient may experience a brief, deep pulling or aching sensation during aspiration. If a biopsy is also required, a small core of bone tissue is obtained using the same or a separate needle. After the needle is removed, firm pressure is applied to the site to control bleeding, and a sterile bandage is placed. The collected specimen is immediately labeled with unique patient identifiers and prepared for transport. Chughtai Lab employs a rigorous, temperature-controlled cold chain protocol to ensure that the specimen is safely transported to the Genetech reference facility without degradation of the sensitive nucleic acids (DNA and RNA) required for molecular analysis.

When is a Acute Myeloid Leukemia (AML) (outsource Genetech) Performed?

Initial Diagnosis and Subtyping of Acute Leukemia

When a patient presents with clinical signs of bone marrow failure, such as unexplained fatigue, recurrent infections, or easy bruising, a complete blood count and peripheral blood smear are performed. If these tests reveal an elevated number of blast cells, the Acute Myeloid Leukemia (AML) (outsource Genetech) test is ordered to confirm the diagnosis of AML. It helps distinguish AML from other hematological malignancies, such as acute lymphoblastic leukemia (ALL) or myelodysplastic syndromes (MDS), and classifies the disease according to the World Health Organization (WHO) criteria based on specific genetic abnormalities.

Prognostic Risk Stratification

AML is a highly heterogeneous disease with widely varying clinical courses. The identification of specific molecular mutations and cytogenetic abnormalities is the most powerful tool available for predicting patient outcomes. For instance, the presence of NPM1 mutations or biallelic CEBPA mutations in the absence of FLT3-ITD mutations indicates a favorable prognosis, whereas mutations in TP53, ASXL1, or RUNX1, or the presence of a complex karyotype, signify adverse risk. This risk stratification allows oncologists to determine whether a patient can be cured with standard chemotherapy alone or if they require an early allogeneic stem cell transplant.

Selection of Targeted Therapeutic Agents

The therapeutic landscape of AML has evolved dramatically with the introduction of targeted therapies. The Acute Myeloid Leukemia (AML) (outsource Genetech) panel identifies actionable genetic mutations that can be targeted with specific drugs. For example, patients with FLT3 mutations may benefit from the addition of FLT3 inhibitors like midostaurin or gilteritinib to their treatment regimen. Similarly, the detection of IDH1 or IDH2 mutations makes patients candidates for targeted IDH inhibitors such as ivosidenib or enasidenib. Identifying these markers ensures that patients receive the most effective, personalized therapeutic options available.

Monitoring Minimal Residual Disease (MRD)

Following the completion of induction chemotherapy, patients may achieve a complete clinical remission, meaning that no leukemia cells are visible under a standard microscope. However, submicroscopic levels of leukemic cells, known as minimal residual disease (MRD), may persist and eventually lead to relapse. This highly sensitive molecular panel can detect specific genetic fusion transcripts (such as RUNX1-RUNX1T1 or CBFB-MYH11) or mutations (such as NPM1) at extremely low levels. Monitoring MRD helps clinicians assess treatment response, predict impending relapse, and make timely adjustments to the therapeutic strategy.

Evaluating Relapsed or Refractory Leukemia

In cases where a patient’s leukemia does not respond to initial therapy (refractory disease) or returns after a period of remission (relapsed disease), repeating the molecular profiling is crucial. Leukemia cells are dynamic and can undergo clonal evolution, acquiring new genetic mutations over time that confer resistance to previously effective treatments. The Acute Myeloid Leukemia (AML) (outsource Genetech) test helps identify these newly acquired resistance mutations, enabling oncologists to modify the treatment plan and explore clinical trials or alternative targeted therapies.

What Does a Acute Myeloid Leukemia (AML) (outsource Genetech) Detect?

The Acute Myeloid Leukemia (AML) (outsource Genetech) panel is designed to detect a wide array of clinically significant genetic and molecular abnormalities. Specifically, this test detects:

• FLT3-ITD Mutations: Internal tandem duplications in the FLT3 gene, which are associated with high leukocytosis and an increased risk of relapse.
• FLT3-TKD Mutations: Point mutations in the tyrosine kinase domain of the FLT3 gene, which also serve as therapeutic targets.
• NPM1 Mutations: Mutations in the nucleophosmin 1 gene, which generally confer a favorable prognosis when present without FLT3-ITD.
• CEBPA Biallelic Mutations: Double mutations in the CEBPA gene, indicating a highly favorable clinical outcome.
• RUNX1-RUNX1T1 Fusion: The t(8;21) translocation, characteristic of core-binding factor AML, associated with a favorable prognosis.
• CBFB-MYH11 Fusion: The inv(16) or t(16;16) chromosomal abnormalities, also representing core-binding factor AML with favorable outcomes.
• PML-RARA Fusion: The t(15;17) translocation, diagnostic for acute promyelocytic leukemia (APL), requiring immediate targeted therapy with ATRA.
• TP53 Mutations: Mutations in the TP53 tumor suppressor gene, associated with extreme chemoresistance and adverse prognosis.
• ASXL1 Mutations: Epigenetic regulator mutations linked to poor prognosis and secondary AML.
• RUNX1 Mutations: Point mutations in the RUNX1 gene, indicating an adverse prognosis in de novo AML.
• IDH1 Mutations: Mutations in the isocitrate dehydrogenase 1 gene, which are targetable with specific IDH1 inhibitors.
• IDH2 Mutations: Mutations in the isocitrate dehydrogenase 2 gene, targetable with specific IDH2 inhibitors.
• DNMT3A Mutations: Mutations in the DNA methyltransferase 3 alpha gene, often occurring early in leukemogenesis.
• KIT Mutations: Mutations in the KIT proto-oncogene, which can adversely affect the prognosis of core-binding factor AML.
• KMT2A (MLL) Rearrangements: Translocations involving the KMT2A gene on chromosome 11q23, associated with intermediate to adverse risk.
• DEK-NUP214 Fusion: The t(6;9) translocation, associated with poor prognosis and often presenting with basophilia.
• GATA2/MECOM Rearrangements: The inv(3) or t(3;3) abnormalities, associated with adverse risk and normal or elevated platelet counts.
• BCR-ABL1 Fusion: The t(9;22) translocation, a rare but clinically significant finding in AML that may respond to tyrosine kinase inhibitors.
• WT1 Overexpression: High levels of Wilms Tumor 1 gene expression, useful as a marker for monitoring minimal residual disease.
• Monosomy 7 (-7): Loss of chromosome 7, associated with adverse prognosis and prior myelodysplastic syndrome.
• Monosomy 5 (-5): Loss of chromosome 5, indicating high genetic instability and adverse risk.
• Complex Karyotype: The presence of three or more clonal chromosomal abnormalities, indicating a highly aggressive disease course.

Turnaround Time and Report Access at Chughtai Lab

Because the Acute Myeloid Leukemia (AML) (outsource Genetech) test involves highly specialized molecular sequencing and is outsourced to Genetech’s advanced reference laboratory, the turnaround time is typically 10 to 15 working days. This duration is necessary to ensure the highest level of analytical precision and comprehensive clinical interpretation of the genetic data. Once the testing is complete and the report is finalized by the expert pathologists at Genetech, it is securely transmitted back to Chughtai Lab. Chughtai Lab immediately uploads the report to its secure online database. Patients and referring oncologists can easily access the results through the Chughtai Lab online portal, the dedicated Chughtai Lab mobile application, or by visiting any Chughtai Lab diagnostic center across Pakistan. This seamless digital access ensures that critical diagnostic information is available to the clinical team without delay, facilitating prompt therapeutic decisions.

Acute Myeloid Leukemia (AML) (outsource Genetech) Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
FLT3 Mutation Status	Not Detected (Wild Type)	FLT3-ITD or FLT3-TKD mutation detected (associated with aggressive disease; guides targeted therapy)
NPM1 Mutation Status	Not Detected (Wild Type)	NPM1 mutation detected (often associated with favorable prognosis in the absence of FLT3-ITD)
CEBPA Mutation Status	Not Detected (Wild Type)	Biallelic CEBPA mutations detected (associated with a highly favorable prognosis)
PML-RARA Fusion	Not Detected	PML-RARA t(15;17) detected (confirms Acute Promyelocytic Leukemia, requiring immediate ATRA therapy)
Core-Binding Factor Fusions	Not Detected	RUNX1-RUNX1T1 or CBFB-MYH11 detected (favorable risk profile)
TP53 Mutation Status	Not Detected (Wild Type)	TP53 mutation detected (associated with adverse risk, complex karyotype, and resistance to standard chemotherapy)
IDH1/IDH2 Mutations	Not Detected (Wild Type)	IDH1 or IDH2 mutations detected (actionable mutations; guides use of targeted IDH inhibitors)
Karyotype Analysis	Normal diploid karyotype (46,XX or 46,XY)	Numerical or structural chromosomal abnormalities (e.g., monosomy 5, monosomy 7, complex karyotype)

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for Acute Myeloid Leukemia (AML) (outsource Genetech)?

• International Collaboration: Chughtai Lab partners with premier international reference laboratories like Genetech to provide advanced molecular testing that meets global standards.
• Specimen Integrity: Strict adherence to temperature-controlled cold chain logistics ensures that sensitive genetic samples are transported without degradation.
• Highly Trained Staff: Phlebotomists and clinical staff are specially trained in the collection and handling of complex oncological specimens.
• Convenient Digital Access: Reports are easily accessible online via the Chughtai Lab website and the dedicated mobile application.
• Extensive Network: With diagnostic centers across Pakistan, patients can easily access services in major cities like Lahore, Karachi, and Islamabad.
• Quality Assurance: Chughtai Lab maintains robust internal and external quality control protocols to ensure maximum diagnostic accuracy.
• Dedicated Patient Support: A professional customer care team is available to assist patients with test inquiries, scheduling, and report retrieval.
• Rapid Clinical Integration: Seamless reporting systems ensure that oncologists receive critical genetic data promptly to initiate timely treatment.